Advertisement

Topics

Melinta Therapeutics and Menarini Group Enter Commercial Agreement

12:56 EDT 1 Oct 2018 | Investing News Network

Melinta Therapeutics (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious bacterial infections, and Menarini Group, an Italian biopharmaceutical group, today announced that they have entered into an agreement under which Menarini will acquire the exclusive rights to co-develop and commercialize Vabomere™ (meropenem and vaborbactam), Orbactiv (oritavancin) and Minocin (minocycline) for … Continued

The post Melinta Therapeutics and Menarini Group Enter Commercial Agreement appeared first on Investing News Network.

Original Article: Melinta Therapeutics and Menarini Group Enter Commercial Agreement

NEXT ARTICLE

More From BioPortfolio on "Melinta Therapeutics and Menarini Group Enter Commercial Agreement"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...